Gh. ]ugulete *, Mariana Miirdiirescu **, Monica Luminos *, S. Petrea, Cristina Petre ***, Ruxandra Măntescu ***
* Ch. Jugulete – medic specialist boli infecțioase, asistent universitar, U.M.F. “Carol Davila” București
** Mariana Mărdărescu, Monica Luminos, S. Petrea – medic primar, șef de secție lnstitutul de Boli
lnfecțioase “Prof. dr. Matei Balș”, București
*** Cristina Petre, Ruxandra Măntescu – medic primar, Institutul de Boli Infecțioase “Prof. dr. Matei Balș”, București
Abstract
In this study we proposed to evaluate efficacy and erability of various antiretroviral regimens on pretreated HIV-infected children. We have monitories for 36 months, clinical and laboratory (CD4 cell count, viral load and bio chemical parameters), 120 pretreated HIV infected children, with ages between 11 -14 years old, hospitalized in Institute of Infectious Diseases “Prof. dr. Matei Balf Bucharest. The children were divided on four groups: first – pretreated with two nucleoside reverse transcriptase inhibitor (NATI), the second with 2 NRTl’s plus one non-nucleoside reverse transcriptase inhibitor (NNRTI), third group with 2 NRTl’s plus one protease inhibitor (Pl) and the last with two or more Pl. Overall the therapy was generally well tolerated for the duration of study. Adverse reactions (rash, nausea, vomiting, abdominal pain and headache) were rare. At months 36 of therapy mean CD4-cell count increased on first group by 264 cells/mm3, 244 cells/mm3 on second group, 186 cells/mm3 on third group and 112 cells/mm3 on fourth group. At months 36 of therapy, VL declining <400 copies/ml at 85 % from children’s first group, 72% from second group, 60 % from third group and 46% from fourth group. Laboratory abnormalities were rare and nor significant.